mt logoMyToken
ETH Gas
عربى

Moderna Stock Doubles, Adding $26.4 Billion After Cancer Vaccine Meets Both Phase 3 Goals

يجمعcollect
شاركshare

Moderna Stock Doubles, Adding $26.4 Billion After Cancer Vaccine Meets Both Phase 3 Goals

Moderna stock more than doubled at its premarket peak Wednesday after the company’s personalized mRNA cancer treatment, developed with Merck, succeeded in a pivotal Phase 3 melanoma trial. MRNA rose by approximately 105% from Tuesday’s $62.96 closing price, reaching an estimated peak near $129.07.

Visit Website

إخلاء المسؤولية: تعود حقوق نشر هذه المقالة إلى المؤلف الأصلي ولا تمثل MyToken(www.mytokencap.com)الآراء والمواقف ؛ يرجى الاتصال بنا إذا كانت لديك أسئلة حول المحتوى وحقوق التأليف والنشر وما إلى ذلك.
community_x_prefix
X(https://x.com/MyTokencap)
community_tg_prefixcommunity_tg_name
https://t.me/mytokenGroup
القراءة ذات الصلة